These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29179455)

  • 41. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia.
    Hong SJ; Kim SI; Kwon SM; Lee JR; Chung BC
    Yonsei Med J; 2002 Apr; 43(2):236-41. PubMed ID: 11971218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
    Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
    J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between benign prostatic hyperplasia and inflammation.
    Bostanci Y; Kazzazi A; Momtahen S; Laze J; Djavan B
    Curr Opin Urol; 2013 Jan; 23(1):5-10. PubMed ID: 23159991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
    Wu Q; Zhou Y; Chen L; Shi J; Wang CY; Miao L; Klocker H; Park I; Lee C; Zhang J
    J Endocrinol; 2007 Oct; 195(1):89-94. PubMed ID: 17911400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
    BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia.
    Wu F; Ding S; Li X; Wang H; Liu S; Wu H; Bi D; Ding K; Lu J
    Oncotarget; 2016 Mar; 7(11):12053-62. PubMed ID: 26919249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
    De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
    Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Relation between benign prostatic hyperplasia and obesity and estrogen].
    Matsuda T; Abe H; Suda K
    Rinsho Byori; 2004 Apr; 52(4):291-4. PubMed ID: 15164594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and single-institutional analysis.
    Hu J; Zhang L; Zou L; Hu M; Fan J; Cai Y; Xu G; Fang J; Ding Q; Jiang H
    Int J Urol; 2015 Dec; 22(12):1138-42. PubMed ID: 26311564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
    Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
    Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation.
    Jiang MY; Han ZD; Li W; Yue F; Ye J; Li B; Cai Z; Lu JM; Dong W; Jiang X; Zhong W; He H; Liu L
    Oncotarget; 2017 Oct; 8(46):80295-80302. PubMed ID: 29113303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.
    Ohtake S; Kawahara T; Ishiguro Y; Takeshima T; Kuroda S; Izumi K; Miyamoto H; Uemura H
    Mol Clin Oncol; 2018 Sep; 9(3):302-304. PubMed ID: 30112175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Regulatory effect of NF-κB on prostatic hyperplasia: Progress in researches].
    Wang KY; Wu JH
    Zhonghua Nan Ke Xue; 2021 Nov; 27(11):1025-1029. PubMed ID: 37422876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etiopathogenesis of benign prostatic hypeprlasia.
    Tang J; Yang J
    Indian J Urol; 2009 Jul; 25(3):312-7. PubMed ID: 19881121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of inflammation in benign prostatic hyperplasia.
    Chughtai B; Lee R; Te A; Kaplan S
    Rev Urol; 2011; 13(3):147-50. PubMed ID: 22110398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correction: Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells.
    Jung Y; Park J; Kim HL; Youn DH; Kang J; Lim S; Jeong MY; Sethi G; Park SJ; Ahn KS; Um JY
    Oncotarget; 2019 Jul; 10(44):4611. PubMed ID: 31360309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.